Springer Nature [academic journals on nature.com], British Journal of Cancer, 6(129), p. 895-896, 2023
DOI: 10.1038/s41416-023-02194-1
Full text: Unavailable
SummaryRecently, Liau et al. reported the results of Phase 3 clinical trial testing DCVax-L vaccines on patients with glioblastoma. Despite the promising and significant results obtained, the study design and the long-lasting period of recruitment of this work deserve some reflection.